Psoriasis is a chronic autoimmune disorder causing inflammation of the skin. The exact cause is unknown, but scientists do know that a large volume of inflammatory cells are released as an immune response, inflaming skin and creating a vicious cycle of inflammation.
As knowledge surrounding T helper cell types increases, scientists have discovered more potential drug targets for treating psoriasis. Cytokine interleukin 17 and others in the IL-17 pathway are the newest drug targets for psoriasis therapies.